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We have recently identified the MAPK phosphatase (MKP)-1
as a novel mediator of the antiinflammatory properties of
glucocorticoids (dexamethasone) in the human endothelium.
However, nothing is as yet known about the signaling path-
ways responsible for theup-regulationofMKP-1bydexameth-
asone in endothelial cells. Knowledge of the molecular basis
of this new alternative way of glucocorticoid action could
facilitate the identification of newantiinflammatorydrug tar-
gets. Thus, the aim of our study was to elucidate the under-
lying molecular mechanisms. Using Western blot analysis, we
found that dexamethasone rapidly activates ERK, c-jun N-
terminal kinase (JNK), and p38 MAPK in human umbilical
vein endothelial cells. By applying the kinase inhibitors
PD98059 (MAPK kinase-1) and SP600125 (JNK), ERK and JNK
were shown to be crucial for the induction of MKP-1. Using
EMSA and a decoy oligonucleotide approach, the transcrip-
tion factors activator protein-1 (activated by ERK and JNK)
and cAMP response element-binding protein (activated by
ERK)were found to be involved in the up-regulation ofMKP-1
by dexamethasone. Interestingly, dexamethasone induces the
generation of reactive oxygen species (measured by dihy-
drofluorescein assay), which participate in the signaling pro-
cess by triggering JNK activation. Our work elucidates a
novel alternative mechanism for transducing antiinflamma-
tory effects of glucocorticoids in the human endothelium.
Thus, our study adds valuable information to the effortsmade
to find new antiinflammatory principles utilized by glucocor-
ticoids. This might help to gain new therapeutic options to
limit glucocorticoid side effects and to overcome resistance.
(Endocrinology 149: 3635–3642, 2008)
SINCE THEIR INTRODUCTION in the 1950s, glucocor-ticoids, such as dexamethasone (Dex), have become
valuable and indispensable drugs used for the treatment of
a plethora of diseases with an inflammatory component, for
instance chronic obstructive pulmonary disorders, rheuma-
toid arthritis, chronic inflammatory bowel diseases, or aller-
gies. Glucocorticoids work by binding to their cytosolic
glucocorticoid receptor (GR), which upon activation trans-
locates to the nucleus. There, it modulates gene transcription
by binding to glucocorticoid response elements in the re-
spective target genes. Although the receptor activates some
antiinflammatory genes (e.g. lipocortin-1), the antiinflamma-
tory properties of glucocorticoids are thought to be pre-
dominantly mediated via a second pathway: The receptor,
without binding to the DNA, inhibits proinflammatory tran-
scription factors, such as nuclear factor-B or activator pro-
tein-1 (AP-1), by a direct protein-protein interaction known
as transrepression (1).
Besides these well-established concepts of action, addi-
tional antiinflammatorymechanisms of glucocorticoids have
been proposed, especially cross-talk between glucocorticoids
and MAPK signaling pathways (2). In recent years, MAPK
phosphatase-1 (MKP-1), the first described member of the
family of dual-specificity phosphatases, has emerged as a
novel glucocorticoid-induced gene (3). In this context, we
recently identified MKP-1 as a mediator of the antiinflam-
matory action of Dex in the human vascular endothelium (4).
The endothelium is a fundamental component of the vascu-
lar system. In addition to its important regulatory functions
regarding vascular permeability, blood pressure, and coag-
ulation, the endothelium is crucially involved in inflamma-
tory response processes. The extravasation of leukocytes
from the blood to the sites of inflammation, tightly controlled
by endothelial cells, is of great importance in this context.
Adhesionmolecules, like E-selectin, are necessary for the first
steps in extravasation, i.e. the adherence of leukocytes to the
endothelium, and are strongly expressed in inflammation-
activated endothelial cells. In the model of TNF--exposed
human endothelial cells, we have previously demonstrated
that an increase of MKP-1 protein is responsible for the
nuclear factor-B-independent reduction of E-selectin ex-
pression caused by Dex at 1 nm. The Dex-induced up-reg-
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ulation of MKP-1 was shown to inhibit TNF--activated p38
MAPK, which is responsible for the TNF--evoked increase
of E-selectin (4).
In general, MKP-1 has increasingly been recognized as an
important negative regulator of inflammatory processes
(5–8) and as a gene up-regulated by glucocorticoids (3). The
concept of MKP-1 as a crucial mediator of the antiinflam-
matory effects of glucocorticoids was recently verified in vivo
(9). Nevertheless, the precise mechanisms that glucocorti-
coids use to regulate MKP-1 are as yet unknown (3). There-
fore, the aim of this study was to clarify the molecular sig-
naling pathways that are responsible for the increased
expression of MKP-1 protein caused by Dex in the human
vascular endothelium.
Materials and Methods
Reagents
The synthetic glucocorticoid dexamethasone [(11,16)-9-fluoro-
11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione], the antioxi-
dants tiron (4,5-dihydroxy-1,3-benzenedisulfonic acid disodium salt)
and N-acetyl-l-cysteine (NAC), and the phosphatidylinositol 3-kinase
(PI3K) inhibitor wortmannin (KY 12420) were from Sigma-Aldrich
(Taufkirchen, Germany). TheMAPKkinase-1 (MEK1) inhibitor PD98059
(2-amino-3-methoxy-flavone) was from Cell Signaling/New England
Biolabs (Frankfurt am Main, Germany). The c-jun N-terminal kinase
(JNK) inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one] and the p38
MAPK inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methyl-sulfinylphe-
nyl)-5-(4-pyridyl)1H-imidazole] were from Calbiochem/EMD Bio-
sciences/Merck (Darmstadt, Germany).
Cell culture
Human umbilical vein endothelial cells were prepared by digestion
of umbilical veins with 0.1 g/liter collagenase A (Roche, Mannheim,
Germany) as previously described (10) and cultured in endothelial cell
growth medium (Promocell, Heidelberg, Germany) containing 10%
heat-inactivated fetal calf serum (Biochrom, Berlin, Germany). Cells of
passage 3 were used in all experiments and were routinely tested for
mycoplasma contaminationwith the PCRdetection kit VenorGeM (Min-
erva Biolabs, Berlin, Germany). Before treatment, cells were starved
overnight in a steroid-freemedium consisting of phenol red-free DMEM
(Bio-Whittaker/Cambrex, Verviers, Belgium) supplemented with 20%
heat-inactivated, charcoal-stripped fetal calf serum (Biochrom).
Immunoblotting
For Western blot analysis, cells were grown in six-well plates until
confluence andwere treated as indicated in the respective figure legend.
Western blot analysis was performed as described previously (10). Anti-
MKP-1 rabbit polyclonal antibody (dilution 1:1000)was from Santa Cruz
(Heidelberg, Germany). Anti-phospho-p44/42 (ERK) MAPK (Thr202/
Tyr204)mousemonoclonal (E10) antibody (dilution 1:2000), anti-p44/42
(ERK) MAPK rabbit polyclonal antibody (dilution 1:1000), and anti-
phospho-SAPK/JNK (Thr183/Tyr185) rabbit monoclonal (98F2) anti-
body (dilution 1:1000) were from Cell Signaling/New England Biolabs.
Horseradish peroxidase-conjugated goat antirabbit antibody was from
Dianova (Hamburg, Germany), and horseradish peroxidase-conjugated
goat antimouse antibody was from Biozol (Eching, Germany). For den-
sitometric analysis, films developed with an AGFA Curix 60 (AGFA,
Cologne, Germany) were analyzed by the Kodak 1D software version
3.5.4 (Eastman Kodak, Rochester, NY). Regarding the densitometric
analysis of JNK and ERK, the JNK1/p-JNK1 and ERK2/p-ERK2 bands
were used for quantification.
EMSA
Cells were grown in six-well plates or 60-mm dishes until confluence
and treated as indicated in the respective figure legend. Nuclear extracts
were prepared and EMSA was performed as described previously (11).
AP-1 consensus oligonucleotides (5-CGCTTGATGAGTCAGCCG-
GAA-3) and cAMP response element-binding protein (CREB) consen-
sus oligonucleotides (5-AGAGATTGCCTGACGTCAGAGAGCTAG-
3) were from Promega (Mannheim, Germany). For densitometric
analysis, the OptiQuant software version 4.00 (PerkinElmer, Rodgau,
Germany) was used.
AP-1 and CREB decoy experiments
Cells were grown in six-well plates until approximately 80% conflu-
ence and were transfected with decoy or scrambled decoy phosphoro-
thioate oligonucleotides by using the SuperFect transfection reagent
(QIAGEN, Hilden, Germany) according to the manufacturer’s instruc-
tions. Experiments were performed 3 h after transfection. AP-1 decoy
(5-cgcttGATGACTCAGCcggaa-3, lowercase letters indicate phospho-
rothioate backbone), AP-1 scrambled decoy (5-cgcttGATGACTTGGC-
cggaa-3), CREB decoy (5-tgacgTCATGACGTCATGAcgtca-3), and
CREB scrambled decoy (5-ctagcTAGCTAGCTAGCTAgctag-3) were
from biomers.net (Ulm, Germany).
Detection of reactive oxygen species (ROS)
Cells were grown in 24-well plates until confluence and treated as
indicated in the respective figure legend. ROS generation was detected
as described previously (12). Briefly, cells were loaded with 20 m
dihydrofluorescein diacetate (Molecular Probes/Invitrogen, Karlsruhe,
Germany) for 20 min. Fluorescence measurements were made 30 min
after treatment. Data were calculated as percent increase of fluorescence
values of untreated cells.
Statistical analysis
The number of independently performed experiments (n) is stated in
the respective figure legend. One representative image is shown. Bar
graph data are expressed as mean  sem. Statistical analysis was per-
formed with GraphPad Prism software version 3.03 (GraphPad, San
Diego, CA). To compare three or more groups, one-way ANOVA fol-
lowed by Tukey’s post hoc test was used. To compare two groups,
Student’s t test was used.
Results
As previously reported by our group, Dex induces the
expression of MKP-1 in human endothelial cells. Maximal
MKP-1 protein expression was observed after 60 min at a
concentration of 1 nm Dex (4). Therefore, this time point and
concentration were chosen for all following experiments re-
garding the induction of MKP-1 by Dex.
Dex treatment leads to an activation of ERK, JNK, and
p38 MAPK
Activated MAPKs up-regulate MKP-1 as a negative
feedback mechanism. Therefore, we hypothesized that
Dex activates these kinases. To judge their activity, the
phosphorylation status at Thr202/Tyr204 (ERK), Thr183/
Tyr185 (JNK), and Thr180/Tyr182 (p38 MAPK) was mea-
sured using Western blot analysis. Indeed, we found that
all three MAPKs, ERK (Fig. 1A), JNK (Fig. 1B), and p38
MAPK (Fig. 1C), are rapidly (within 5–15 min) activated
by Dex. This activation is transient and starts disappearing
after 60 min.
ERK and JNK play a crucial role in the induction of
MKP-1 by Dex, whereas no involvement of p38 MAPK or
PI3K could be demonstrated
To test whether andwhichMAPK is in fact responsible for
the Dex-induced up-regulation of MKP-1, pharmacological
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MAPK inhibitors were employed: PD98059 for MEK1,
SP600125 for JNK, and SB203580 for p38 MAPK inhibition,
respectively. ERK (Fig. 2A) and JNK (Fig. 2B) were found to
mediate the induction of endothelial MKP-1 by Dex, but no
involvement of p38 MAPK could be demonstrated (Fig. 2C).
Because the PI3K/Akt pathway is known to mediate effects
of glucocorticoids in endothelial cells (13, 14), we checked for
an involvement of this pathway in the up-regulation of
MKP-1. The PI3K inhibitor wortmannin was not able to in-
hibit the effect of Dex onMKP-1 protein expression (Fig. 2D),
suggesting that the PI3K/Akt pathway does not play a cru-
cial role.
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FIG. 1. Dex treatment time-dependently activates ERK, JNK, and
p38 MAPK. A, Dex activates ERK (p42/p44) (n  4); B, Dex activates
JNK (p46/p54) (n 3); C, Dex activates p38MAPK (n 4). Cells were
either left untreated or were treated with Dex (1 nM) for the indicated
times. Levels of phospho-ERK, total ERK, phospho-JNK, total JNK,
phospho-p38MAPK, and total p38MAPKproteinwere determined by
immunoblotting as described in Materials and Methods. Numbers
above the images represent the results (SEM) of the densitometric
analysis. *, P  0.05 vs. untreated cells.
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FIG. 2. ERK and JNK, but not p38 MAPK or PI3K, are crucially
involved in the Dex-induced up-regulation of MKP-1. A, ERK is in-
volved in the up-regulation of MKP-1 by Dex. Cells were either left
untreated or treated with Dex (1 nM, 60 min) in the presence or
absence of theMEK1 inhibitor PD98059 (10M, 60min pretreatment)
(n  4). B, JNK is involved in the induction of MKP-1 by Dex. Cells
were either left untreated or treated with Dex (1 nM, 60 min) in the
presence or absence of the JNK inhibitor SP600125 (10 M, 60 min
pretreatment) (n  4). C, p38 MAPK does not participate in Dex-
induced increase of MKP-1 protein expression. Cells were either left
untreated or treated with Dex (1 nM, 60 min) in the presence or
absence of the p38 MAPK inhibitor SB203580 (10 M, 60 min pre-
treatment) (n  3). D, PI3K is not involved in the up-regulation of
MKP-1 by Dex. Cells were either left untreated or treated with Dex
(1 nM, 60 min) in the presence or absence of the PI3K inhibitor
wortmannin (50 nM, 30 min pretreatment) (n  3). Levels of MKP-1
proteinwere determined by immunoblotting as described inMaterials
andMethods.Numbers above the images represent the results (SEM)
of the densitometric analysis. *, P  0.05 vs. untreated cells; #, P 
0.05 vs. cells treated with Dex only; ns, P 0.05 vs. cells treated with
Dex only.
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ERK- and JNK-activated AP-1 plays a pivotal role in the
up-regulation of MKP-1 by Dex
An increase of MKP-1 protein levels is predominantly
achieved by transcriptional mechanisms, i.e. the activation
of transcription factors. Our hypothesis was that the tran-
scription factor AP-1 could be involved. First, by perform-
ing EMSA, we checked whether Dex is able to activate
AP-1. We found that AP-1 is rapidly (within 5 min) acti-
vated by Dex (Fig. 3A). This activation fades after 30 min,
and a second activation peak emerges after 60 min, sug-
gesting a biphasic Dex-induced AP-1 activity course. The
role of AP-1 for the induction of MKP-1 was investigated
via an AP-1 decoy approach: cells transfected with AP-1
decoy, but not with the scrambled decoy, lose the ability
to elevate MKP-1 protein levels upon Dex treatment (Fig.
3B, left panel). The AP-1 decoys were proven to not influ-
ence basal protein levels of MKP-1 (Fig. 3B, right panel).
These data point to a crucial role for AP-1 in the signaling
pathway mediating the Dex-evoked induction of endo-
thelial MKP-1. Moreover, we were interested in the ques-
tion whether this Dex-induced AP-1 activity is caused by
the Dex-induced activation of ERK or JNK. Using phar-
macological inhibitors, both kinases were shown to me-
diate the Dex-induced AP-1 DNA-binding activity (Fig.
3C), suggesting that the signals of these two Dex-activated
MAPKs converge on the AP-1 transcription factor.
ERK-activated CREB is also causally involved in the
induction of MKP-1 by Dex
We hypothesized that, besides AP-1, the transcription
factor CREB participates in the induction ofMKP-1. In fact,
the CREB DNA-binding activity was increased by Dex
within 5 min (Fig. 4A), and, comparable to the activation
pattern of AP-1, the activity of CREB decreases after 15min
and a second activation peak appears within 60 min of Dex
treatment. The causal link between the CREB activation
and the induction of MKP-1 was established by using a
CREB decoy approach; Dex is not able to increase MKP-1
protein levels in the presence of CREB decoy oligonucle-
otides (Fig. 4B, left panel). The CREB decoys were proven
to not influence basal protein levels of MKP-1 (Fig. 4B,
right panel). Because Dex activates ERK and ERK is known
to influence CREB activity, we assumed that the Dex-
induced ERK is involved in the activation of CREB. Indeed,
we could show that the Dex-evoked increase of CREB
DNA-binding activity is abrogated in endothelial cells
treated with the MEK1 inhibitor PD98059 (Fig. 4C). These
data suggest that the ERK-induced activation of CREB is
pivotal for an up-regulation of MKP-1 by Dex.
The Dex-induced generation of ROS is crucial for the
induction of MKP-1 and the activation of JNK
We could recently demonstrate that ROS are able to up-
regulate endothelialMKP-1 protein levels (12). Therefore, we
hypothesized that Dex could induce MKP-1 via the forma-
tion of ROS. First, we tested whether Dex treatment leads to
augmentedROS levels: Endothelial cellswere loadedwith an
ROS-sensitive dye (dihydrofluorescein diacetate), and the
generation of ROS was measured upon treatment with dif-
ferent Dex concentrations (1–1000 nm). As shown in the left
panel of Fig. 5A, Dex concentration-dependently increased
the formation of endothelial ROS. Antioxidants, such as tiron
and NAC, which effectively lower intracellular ROS levels
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FIG. 3. ERK- and JNK-activated AP-1 plays a pivotal role in the
induction of MKP-1 by Dex. A, Dex treatment leads to an activation
of AP-1. Cells were either left untreated or were treated with Dex (1
nM) for the indicated times (n 4). B, AP-1 is crucially involved in the
up-regulation of MKP-1 by Dex. Cells were transfected with AP-1
decoy or scrambled decoy phosphorothioate oligonucleotides as de-
scribed in Materials and Methods. Left panel, Cells were left un-
treated or treated with Dex (1 nM, 60 min) (n  4); right panel, cells
were left untreated to compare the influence of decoy treatment on
basal MKP-1 protein levels (n  4). C, ERK and JNK mediate the
activation of AP-1 by Dex. Cells were either left untreated or treated
with Dex (1 nM, 15 min) in the presence or absence of the MEK1
inhibitor PD98059 (10 M, 60 min pretreatment) (n  4) or the JNK
inhibitor SP600125 (10 M, 60 min pretreatment) (n 3). AP-1 DNA-
binding activity was determined by EMSA, and levels of MKP-1 pro-
tein were determined by immunoblotting as described in Materials
andMethods.Numbers above the images represent the results (SEM)
of the densitometric analysis. *, P  0.05 vs. untreated cells; #, P 
0.05 vs. cells treated with Dex only; ns, P 0.05 vs. cells treated with
scrambled decoy.
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(Fig. 5A, right panel), were able to prevent the Dex-induced
increase of MKP-1 protein (Fig. 5B), pointing to a pivotal role
for ROS in the up-regulation of MKP-1 by Dex. Moreover,
because we found that ERK and JNK are responsible for the
induction of MKP-1, we checked whether ROS are respon-
sible for the activation of these kinases. In the presence of the
antioxidant NAC, Dex forfeits its ability to activate JNK but
not ERK (Fig. 5C), suggesting that the Dex-induced ROS
formation is solely important for the activation of the JNK/
AP-1 pathway, but not for the ERK/AP-1 and ERK/CREB
pathway (Fig. 6).
Discussion
In recent years, the phosphatase MKP-1 has increasingly
been discussed as an interesting pharmacological target due
to its role as amediator of antiinflammatory properties (5–8).
Moreover, MKP-1 has been shown to be a glucocorticoid-
induced gene (3). Hence, the hypothesis ofMKP-1 as a crucial
transducer of the antiinflammatory effects of glucocorticoids
has emerged and was corroborated by an in vivo study (9).
In this context, we could recently show that MKP-1 repre-
sents a novel mediator of the antiinflammatory effects of
glucocorticoids at low concentrations in human endothelial
cells (4); Dex attenuates the TNF--evoked E-selectin expres-
sion via an induction of MKP-1. Both MKP-1 mRNA and
protein levels rise upon Dex treatment (maximal protein
expression at 1 nm Dex after 60 min) (4). Despite this knowl-
edge, themolecularmechanisms underlying the induction of
MKP-1 are still very poorly investigated (3), and no data have
as yet been available concerning the pathways by which Dex
increases the expression of MKP-1 in the human endothe-
lium. Thus, it is of great interest to clarify the signaling
mechanisms Dex (1 nm, 60 min) uses to augment the cellular
MKP-1 levels. We found that the transcription factors AP-1
and CREB are both necessary to increase the expression of
MKP-1 upon Dex treatment. The activity of AP-1 is induced
by the MAPKs ERK and JNK, and CREB is activated by JNK.
For the activation of JNK, but not ERK, the Dex-evoked
generation of ROS was found to play a crucial role (Fig. 6).
The finding that JNK and ERK are involved in the induc-
tion of MKP-1 is in accordance with studies that have pro-
posed a negative feedback loop betweenMAPKs andMKP-1;
i.e. activated MAPKs are able to induce MKP-1 to terminate
their own activity (15–18). MAPKs play an intriguing role in
the molecular pathways affected by glucocorticoids. On the
one hand,MAPKs (particularly JNKandp38MAPK) arewell
known to be strongly involved in the mediation of inflam-
matory effects of different stimuli (e.g. TNF-, IL-1, and li-
popolysaccharide). In their role as inflammatory mediators,
MAPKs are suppressed by glucocorticoids (19). On the other
hand, MAPKs participate in the regulation of antiinflamma-
tory actions, because our data show that they are involved in
the induction of the antiinflammatory mediator MKP-1. In
this role, MAPKs are activated by glucocorticoids. This am-
biguous role highlights the fact that MAPKs are part of a
highly complex spatiotemporal signaling network.
The regulation of MKP-1 activity is mainly achieved by
influencing its transcription; MKP-1 is constitutively ex-
pressed at a low level and underlies, as an immediate-early
gene product (20), a tight and rapid transcriptional up-reg-
ulation by different stimuli. In fact, Dex was shown to in-
crease the expression of MKP-1 mRNA in our setting (4). We
for the first time provide evidence that the transcription
factors CREB (activated by ERK) and AP-1 (activated by JNK
and ERK) are both necessary for the induction of endothelial
MKP-1 by glucocorticoids. This is in line with a study dem-
onstrating that the MKP-1 promoter region contains binding
domains for both transcription factors (21). The fact that the
blockade of each of these factors completely inhibits MKP-1
induction suggests a cooperative action of AP-1 and CREB.
Our work for the first time describes the transcription factor
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FIG. 4. ERK-activated CREB is also causally involved in the induc-
tion of MKP-1 by Dex. A, Dex treatment leads to an activation of
CREB. Cells were either left untreated or treated with Dex (1 nM) for
the indicated times (n  4). B, CREB is crucially involved in the
up-regulation of MKP-1 by Dex. Cells were transfected with CREB
decoy or scrambled decoy phosphorothioate oligonucleotides as de-
scribed in Materials and Methods. Left panel, Cells were left un-
treated or were treated with Dex (1 nM, 60 min) (n  3); right panel,
cells were left untreated to compare the influence of decoy treatment
on basal MKP-1 protein levels (n  4). C, ERK plays a pivotal role in
the Dex-induced activation of CREB. Cells were either left untreated
or treated with Dex (1 nM, 5 min) in the presence or absence of the
MEK1 inhibitor PD98059 (10M, 60minpretreatment) (n 3). CREB
DNA-binding activity was determined by EMSA, and levels of MKP-1
proteinwere determined by immunoblotting as described inMaterials
andMethods.Numbers above the images represent the results (SEM)
of the densitometric analysis. *, P  0.05 vs. untreated cells; #, P 
0.05 vs. cells treated with Dex only; ns, P 0.05 vs. cells treated with
scrambled decoy.
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CREB as transducer of antiinflammatory actions of glucocor-
ticoids in the vascular endothelium. This phenomenon has as
yet been found only in lymphoblastic cells (22). AP-1 is
known to be a typical proinflammatory transcription factor,
which is inactivated by glucocorticoids via the classic mech-
anism of transrepression (1). Here, we present AP-1 as a
mediator of antiinflammatory actions, because it induces
MKP-1. This is in line with studies showing that AP-1 is able
to transduce the antiinflammatory effects of natriuretic pep-
tides (12) or salicylates (23). The controversial role of AP-1
could depend on the prevailing activation status of AP-1;
Dex, natriuretic peptides, and salicylates were applied to
resting, nonactivated endothelial cells, whereas the inhibi-
tory role of glucocorticoids on AP-1 was investigated in
inflammation-stressed cells.
Investigations into the mechanisms upstream of the
MAPK activation revealed that Dex evokes the generation of
ROS, which are crucially involved in the up-regulation of
MKP-1 by activating JNK. It has to be stressed that the glu-
cocorticoid-induced formation of ROS in endothelial cells
has as yet been shown only in the context of side effects of
a chronic glucocorticoid excess on the vascular system (24):
The Dex-induced long-time ROS formation was regarded as
a deleterious event leading to endothelial dysfunction. In
contrast, we provide evidence that glucocorticoid-evoked
ROS can also serve as important signalingmolecules relaying
antiinflammatory effects. This is in linewith studies showing
that ROS can be more than deleterious molecules, because
they were also found to be important mediators or triggers
of beneficial actions in endothelial cells (12, 25). Interestingly,
the generation of ROS keeps rising with ascending Dex con-
centrations (1–1000 nm), whereas the induction of MKP-1 is
maximal at 1 nm and dwindles at higher concentrations (10
nm), as was previously reported by our group (4). In accor-
dance with the above mentioned signaling functions of ROS,
we speculate that only small amounts of ROS lead to an
up-regulation of MKP-1 and that these small amounts could
represent signaling ROS, which transduce an antiinflamma-
tory signal. Higher ROS concentrations might participate in
the action of Dex on different signaling pathways or might
even be regarded as the above mentioned deleterious ROS
that are associated with the side effects of a glucocorticoid
therapy. This interesting issue needs further investigations to
gain deeper insights into the detailed role of ROS in the
signaling of Dex.
Glucocorticoid effects can be divided into long-term
genomic effects (i.e. the translocation of the GR into the
nucleus and the subsequent regulation of gene expression)
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and JNK activation. A, Left panel, Dex
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tion. Cells were either left untreated or
treated with tiron (10 mM, 30 min pre-
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and Methods. B, Antioxidants inhibit
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were either left untreated or treated
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NAC (10 mM, 30 min preincubation)
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and short-termnongenomic effects (i.e. glucocorticoids either
nonspecifically alter the physicochemical properties of the
cell membrane or specifically activate a cell membrane-as-
sociated or cytosolic GR) (26). By using a GR antagonist
(RU486), we have previously demonstrated that the rapid
Dex-induced increase ofMKP-1 protein expression in human
umbilical vein endothelial cells depends on the activation of
the GR (4). Because the promoter region of MKP-1 does not
contain glucocorticoid responsive element sequences (21),
we assume that MKP-1 is up-regulated without an involve-
ment of GR-DNA interaction but by an initiation of a rapid
signaling cascade (ROS-MAPK-AP-1/CREB). Thus, we here
describe a specific nongenomic effect of Dex in the human
endothelium.
A growing number of studies report that nongenomic
effects participate in the physiological or pharmacological
action of steroid hormones. For glucocorticoids, effects such
as the influence on intracellular calcium levels in rat pheo-
chromocytoma cells (27), the inhibition of phagocytosis and
superoxide production in mouse peritoneal macrophages
(28), the blockage of human neutrophil degranulation (29),
the focal adhesion kinase- and paxillin-regulated actions on
the actin cytoskeleton in human endometrial adenocarci-
noma cells (30), or the inhibition of the recruitment of sig-
naling factors to activated epidermal growth factor receptors
leading to a decreased liberation of arachidonic acid from
human adenocarcinoma cells, were demonstrated to be non-
genomic. Some of these effects have been suggested to de-
pend on a membrane-associated GR. Interestingly, classic
steroid receptors, such as the estrogen receptor (31), the pro-
gesterone receptor (32), or the mineralocorticoid receptor
(33), have been found to signal at the plasma membrane in
a nongenomic way. Because the nongenomic induction of
MKP-1 completely depends on the classic GR, the question
arises whether this GR is located in the cytosol or associated
with the plasma membrane. In humans, membrane-bound
GRs have as yet primarily been found in immune cells (34).
The precise role of these receptors in mediating effects of
glucocorticoids has still not been unraveled. Thus, clarifying
whether a membrane-bound GR exists in endothelial cells
and whether this receptor participates in the initiation of the
studied signaling cascade is of great interest and warrants
future investigations.
To the best of our knowledge, only two studies have as yet
reported that glucocorticoids are able to induce a non-
genomic, GR-dependent effect in endothelial cells. High-
dose Dex was found to exert cardiovascular protection [i.e.
decreased vascular inflammation and reduced myocardial
infarct size after ischemia/reperfusion injury (13)] and neu-
roprotective effects [i.e. augmented cerebral flow and re-
duced cerebral infarct size after transient cerebral ischemia
(14)]. Both phenomena are based on the activation of endo-
thelial NO synthase and involve a nongenomic but GR-de-
pendent activation of the PI3K/Akt pathway (13, 14). Thus,
we hypothesized that this pathway could also participate in
the induction of MKP-1. However, no involvement of PI3K
in the Dex-induced up-regulation of MKP-1 could be
detected.
The genomic effects of glucocorticoids are generally
thought to be the main cause for side effects limiting their
therapeutic use. To gain novel therapeutic options, i.e. to find
new antiinflammatory principles and, thus, pharmacological
targets, it is of great importance to investigate alternative
pathways by which the antiinflammatory properties of glu-
cocorticoids aremediated. Therefore, the basic research deal-
ing with nongenomic effects has recently been brought into
the focus (34). In this regard, our data add new and valuable
information to this field, because we elucidated the molec-
ularmechanisms bywhichMKP-1, a novel antiinflammatory
mediator used by glucocorticoids, is induced in the human
vascular endothelium.
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